Orion Portfolio Solutions LLC Sells 153,598 Shares of Haleon plc (NYSE:HLN)

Orion Portfolio Solutions LLC decreased its holdings in Haleon plc (NYSE:HLN - Free Report) by 28.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 389,472 shares of the company's stock after selling 153,598 shares during the period. Orion Portfolio Solutions LLC's holdings in Haleon were worth $4,121,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Chartwell Investment Partners LLC increased its stake in shares of Haleon by 107.8% in the third quarter. Chartwell Investment Partners LLC now owns 475,415 shares of the company's stock worth $5,030,000 after purchasing an additional 246,594 shares in the last quarter. Townsquare Capital LLC grew its stake in Haleon by 29.8% during the third quarter. Townsquare Capital LLC now owns 475,618 shares of the company's stock valued at $5,032,000 after acquiring an additional 109,217 shares in the last quarter. Cetera Advisors LLC grew its stake in Haleon by 524.3% during the first quarter. Cetera Advisors LLC now owns 81,991 shares of the company's stock valued at $696,000 after acquiring an additional 68,857 shares in the last quarter. Cetera Investment Advisers grew its stake in Haleon by 106.3% during the first quarter. Cetera Investment Advisers now owns 233,788 shares of the company's stock valued at $1,985,000 after acquiring an additional 120,447 shares in the last quarter. Finally, FORA Capital LLC purchased a new position in Haleon during the third quarter valued at approximately $1,026,000. Hedge funds and other institutional investors own 6.67% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Morgan Stanley boosted their price objective on shares of Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a research note on Friday, September 20th. UBS Group upgraded shares of Haleon to a "strong-buy" rating in a research report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $10.95.

Haleon Price Performance

Haleon stock traded up $0.02 during mid-day trading on Tuesday, hitting $9.67. 6,431,284 shares of the company traded hands, compared to its average volume of 5,337,325. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The stock has a market cap of $43.75 billion, a price-to-earnings ratio of 28.43, a price-to-earnings-growth ratio of 2.92 and a beta of 0.28. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a fifty day moving average price of $9.79 and a 200-day moving average price of $9.50.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.